Brought to you by 
Shire gets ex-NA rights to Acceleron's ACE031, others; terminated
08 Dec 2015
Executive Summary
Acceleron Pharma Inc. (developing drugs that stimulate the growth of red blood cells, bone, muscle, and fat) has licensed specialty pharmaco Shire PLC, through its Shire Human Genetic Therapies Inc., exclusive rights outside North America to compounds targeting the activin receptor type IIB (ActRIIB) pathway, including the Phase IIa therapeutic protein ACE031 for Duchenne muscular dystrophy (DMD).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire gets ex-NA rights to Acceleron's ACE031, others; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice